Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Rhea-AI Summary

Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage biotechnology company focused on heart disease, announces CEO Faraz Ali's participation in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. He will engage in a fireside chat on April 24, 2023, at 1:30 PM ET, followed by a panel discussion titled Gene Therapy: Positioning for CMC Success at Every Stage on April 25, 2023, at 12:00 PM ET. A webcast of the fireside chat will be available on Tenaya's website. Tenaya focuses on developing therapies for genetic cardiovascular disorders, including leading candidates like TN-201 for HCM and TN-401 for ARVC.

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. Details of participation are as follows:

Fireside Chat
Date: April 24, 2023
Time: 1:30 PM ET

Panel - Gene Therapy: Positioning for CMC Success at Every Stage
Date: April 25, 2023
Time: 12:00 PM ET

A webcast of the fireside chat will be available by visiting the Investors section of Tenaya’s website.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.

Contacts

Investors
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com

Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com

FAQ

What is Tenaya Therapeutics participating in on April 24, 2023?

Tenaya Therapeutics will have CEO Faraz Ali in a fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit.

When is the fireside chat featuring Faraz Ali?

The fireside chat with Faraz Ali is scheduled for April 24, 2023, at 1:30 PM ET.

What discussion will Tenaya Therapeutics participate in on April 25, 2023?

On April 25, 2023, Tenaya Therapeutics will participate in a panel discussion titled 'Gene Therapy: Positioning for CMC Success at Every Stage'.

Where can I watch the webcast of the fireside chat?

The webcast of the fireside chat will be available on Tenaya Therapeutics' website in the Investors section.

What conditions does Tenaya Therapeutics focus on with its therapies?

Tenaya Therapeutics develops therapies for genetic cardiovascular disorders, including hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.